CenterBook Partners’s Royalty Pharma RPRX Stock Holding History

CenterBook Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Sell	31,095 -126,082	-80%	-$6.56M	0.09%	260
2026 Q1	$7.54M	Buy	157,177 +86,965	+124%	+$3.81M	0.41%	60
2025 Q4	$2.71M	Sell	70,212 -18,104	-20%	-$690K	0.13%	210
2025 Q3	$3.12M	Sell	88,316 -70,706	-44%	-$2.56M	0.15%	189
2025 Q2	$5.73M	Buy	159,022 +96,015	+152%	+$3.18M	0.32%	85
2025 Q1	$1.96M	Sell	63,007 -41,728	-40%	-$1.32M	0.12%	199
2024 Q4	$2.67M	Sell	104,735 -113,525	-52%	-$3.01M	0.16%	166
2024 Q3	$6.17M	Buy	+218,260	New	+$6.05M	0.38%	81

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CenterBook Partners's RPRX Position: Q2 2026 in Review

CenterBook Partners reduced its Royalty Pharma (RPRX) stake by 80% in Q2 2026, selling an estimated $6.56M and leaving 31,095 shares worth $1.74M. The position accounts for 0.09% of the portfolio, ranked #260.

CenterBook Partners first reported a position in RPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.54M in Q1 2026. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

CenterBook Partners held 31,095 shares of Royalty Pharma worth $1.74M as of Q2 2026.
CenterBook Partners sold 126,082 Royalty Pharma shares in Q2 2026, an estimated $6.56M.
Royalty Pharma made up 0.09% of CenterBook Partners's portfolio in Q2 2026, its #260 holding.
CenterBook Partners first reported a position in Royalty Pharma in Q3 2024 and has held it in 8 quarters since.
CenterBook Partners's Royalty Pharma position peaked at $7.54M in Q1 2026.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.